Fact-checked by Grok 2 weeks ago

Selamectin

Selamectin is a semi-synthetic macrocyclic of the class, formulated as a topical parasiticide for veterinary use in and to treat and prevent a range of ecto- and endoparasitic infections. It is applied monthly to at the base of the , with dosing starting at 6 weeks of age for and 8 weeks for , and is marketed under brand names such as and Stronghold. Chemically, it has the molecular formula C43H63NO11 and a molecular weight of 769.96 g/mol, derived from natural avermectins produced by the bacterium . In dogs, selamectin is indicated for killing adult fleas (Ctenocephalides felis), preventing flea eggs from hatching, preventing heartworm disease caused by Dirofilaria immitis, treating and controlling ear mites (Otodectes cynotis), sarcoptic mange (Sarcoptes scabiei), American dog ticks (Dermacentor variabilis). For cats, it targets flea infestations (Ctenocephalides felis), heartworm prevention, ear mites, roundworms (Toxocara cati), hookworms (Ancylostoma tubaeforme), ticks (Dermacentor variabilis, Ixodes scapularis, others), and prevention of tapeworms (Dipylidium caninum) via flea control. Its mechanism of action involves binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, paralysis, and death of parasites, while showing selectivity that minimizes effects on mammalian hosts. Approved by the U.S. in 1999 under NADA 141-152 for use in companion animals, selamectin has become a of monthly parasitic due to its broad-spectrum and favorable profile in healthy, breeding, and lactating animals, though it is not recommended for debilitated or heartworm-positive dogs without prior testing. Common adverse reactions are rare but may include transient at the application site, , or , with post-approval reports noting occasional neurological effects in sensitive breeds like Collies. As of January 2025, the combination product Plus (selamectin/sarolaner) for cats includes an expanded indication for prevention of tapeworm infections.

Veterinary uses

Indications in dogs

Selamectin is approved for use in dogs for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of flea infestations (Ctenocephalides felis). It is also indicated for the treatment and control of ear mite infestations (Otodectes cynotis) and sarcoptic mange (Sarcoptes scabiei). Additionally, selamectin controls tick infestations caused by Dermacentor variabilis (American dog tick). The recommended dosing regimen for dogs is topical application at a minimum dose of 6 mg/kg body weight once monthly, with treatment suitable for puppies 6 weeks of age and older. Dosage is determined by body weight, using pre-measured single-dose tubes applied to the skin at the base of the neck. Clinical trials have demonstrated high efficacy across these indications. For heartworm prevention, monthly administration of selamectin achieved 100% efficacy in preventing development of adult worms following experimental exposure, with all treated dogs testing negative for microfilariae and antigen. Against fleas, selamectin kills greater than 98% of adult fleas within 36 hours of treatment and provides over 90% control of reinfestations for up to 30 days. In field studies for sarcoptic mange, approximately 90% of dogs showed resolution of clinical signs after two monthly doses. A single dose treats ear mite infestations effectively in most cases, though a second dose may be required for complete elimination. For tick control, monthly dosing reduces Dermacentor variabilis infestations, with a second dose recommended after 14 days for heavy burdens. Selamectin is safe for use in collies and other herding breeds carrying the MDR1 gene mutation at approved doses, with no adverse reactions observed in targeted safety studies of ivermectin-sensitive dogs.

Indications in cats

Selamectin is approved for use in cats to prevent heartworm disease caused by through monthly topical application, which provides complete protection against larval development when administered as directed. It also treats and controls flea infestations (), killing adult fleas and preventing flea egg hatching for up to one month, with efficacy rates of 98-100% in reducing flea counts in clinical studies. In addition to ectoparasites, selamectin addresses common , including treatment and control of infestations (Otodectes cynotis), with over 99% efficacy in eliminating mites by day 30 post-treatment. It effectively treats roundworm () and (Ancylostoma tubaeforme) infections, achieving 98.8-100% reduction in fecal egg counts after one or two monthly doses. Furthermore, selamectin controls biting lice (Felicola subrostratus), demonstrating 100% efficacy in killing lice on treated cats in controlled studies, particularly in European approvals. The recommended dosing regimen is a topical application at a minimum of 6 mg/kg body weight once monthly, with weight-based tube sizes ensuring accurate delivery for cats from 2.6 pounds (1.2 kg) upward. Selamectin is safe for kittens 8 weeks of age or older, a threshold higher than for dogs to account for feline development. Flea control with selamectin overlaps with canine applications but is tailored here to feline-specific parasites like roundworms and lice.

Off-label uses

Selamectin, a broad-spectrum endectocide, has been employed off-label in for the of nasal mites (Pneumonyssoides caninum), with studies demonstrating 100% following three topical applications at doses of 6-24 mg/kg every two weeks. In cats, it has shown effectiveness against (Notoedres cati), achieving resolution with a single topical dose of 6 mg/kg in reported cases. For , oral selamectin at 24-48 mg/kg administered weekly or biweekly resulted in remission in 9 of 38 with juvenile-onset disease, but none with adult-onset, indicating limited overall success and variable response based on clinical severity. In exotic pets, selamectin is commonly used off-label for ectoparasite control, such as mites and fleas in rabbits, ferrets, rats, and birds, often at adjusted doses due to lack of species-specific labeling. In rabbits, topical application at 15 mg/kg has proven effective for sarcoptic mange (Sarcoptes scabiei var. cuniculi), with clinical improvement observed within 15 days after a single dose and complete mite elimination in all treated animals following two doses at 18 mg/kg in small-scale studies. Similar efficacy has been reported for psoroptic mange (Psoroptes cuniculi) and Cheyletiella mites in rabbits at doses up to 15 mg/kg monthly, with resolution rates approaching 90-100% in clinical cases, though formal large-scale trials are absent. In ferrets, it treats fleas (Ctenocephalides felis) and ear mites (Otodectes cynotis) at standard canine/feline doses of 6-12 mg/kg, showing high practical success without reported failures. For rats and mice, doses of 30-45 mg/kg every 1-2 weeks effectively eliminate fur mites and lice (Polyplax spp.), based on veterinary case reports. In birds, such as budgerigars, topical selamectin targets chewing lice and knemidocoptic mites, with anecdotal efficacy in controlling infestations when applied at 15-20 mg/kg, though data remain limited to observational use. Despite these applications, of selamectin in non-target species requires veterinary supervision, as safety profiles vary and formal approval is lacking, potentially necessitating dose adjustments to avoid under- or overdosing. Adverse effects are rare and mild across reports, including transient or in dogs and no significant issues in exotics, but long-term data in and is sparse, emphasizing the need for .

Pharmacology

Mechanism of action

Selamectin is a semisynthetic , belonging to the class of macrocyclic lactones, derived from the fermentation products of the soil actinomycete . The primary mechanism of action of selamectin involves binding to glutamate-gated channels (GluCl) in the nerve and muscle cells of , which opens these ligand-gated ion channels and increases membrane permeability to ions. This influx of leads to hyperpolarization of the postsynaptic membrane, disrupting normal neurotransmission, resulting in and death of the targeted parasites. Unlike in vertebrates, where such channels are absent, this selective targeting exploits the unique physiology of nervous systems. Selamectin demonstrates stage-specific activity within its spectrum of efficacy; it is ineffective against adult heartworms (Dirofilaria immitis) but potently kills circulating microfilariae and third- and fourth-stage larvae (L3 and L4), thereby preventing the maturation and establishment of adult infections. Against fleas (Ctenocephalides felis), selamectin provides adulticidal effects while also exerting ovicidal activity that prevents egg hatching and larvicidal effects that inhibit larval development, effectively breaking the flea life cycle. The selectivity of selamectin for over mammals arises from its substantially lower affinity for mammalian (GABA)-gated chloride channels compared to invertebrate GluCl channels, combined with the protective role of the blood-brain barrier and P-glycoprotein-mediated efflux pumps that restrict drug penetration into the mammalian . This minimizes neurotoxic effects in treated animals, as mammalian GABA receptors are primarily confined to the brain and .

Pharmacokinetics

Selamectin is rapidly absorbed through the skin following topical administration at the recommended dose of 6 mg/kg in both dogs and , with peak concentrations (Cmax) occurring approximately 1 day post-administration in and 3 days in dogs. In , the Cmax is substantially higher (around 5,500 ng/mL at higher experimental doses) compared to dogs (around 85 ng/mL), reflecting greater systemic of approximately 74% in versus 4-5% in dogs. This rapid uptake ensures detectable levels within hours, supporting sustained efficacy against parasites. Following absorption, selamectin exhibits a wide , estimated at 1.2-2.2 L/kg based on intravenous data, indicating extensive tissue penetration and accumulation in lipophilic compartments such as and . It minimally crosses the blood-brain barrier due to efflux by transporters, limiting exposure. Selamectin undergoes limited hepatic metabolism to less active metabolites, with metabolism proceeding more slowly in cats than in dogs, contributing to prolonged exposure in felines. Excretion occurs mainly via the fecal route through biliary elimination, with minor urinary clearance of unmetabolized drug; the terminal elimination is approximately 8 days in and 11 days in after topical dosing. These differences, including higher and more persistent concentrations in , underpin selamectin's broader of activity against intestinal parasites in felines compared to canines.

Adverse effects

In treated animals

In dogs and cats treated with selamectin, the most commonly reported adverse effects are mild and transient, primarily involving the application site. These include localized alopecia with or without (such as or flaking), occurring in approximately 1% of treated in pre-approval clinical trials. Temporary hair clumping, stiffening, or a powdery residue at the site may also appear but typically resolves within 24 hours without intervention. If the animal licks the application site shortly after administration, transient may occur due to the bitter of the , though this is not indicative of systemic . Mild gastrointestinal disturbances, such as or (with or without blood), are less frequent, affecting ≤0.5% of treated animals in clinical studies. Other occasional signs include anorexia, lethargy, or pruritus, also reported at ≤0.5% incidence. Rare adverse effects include neurological signs such as tremors or , particularly in avermectin-sensitive breeds like Collies when exposed to five times the recommended dose, reflecting class-related sensitivity to macrocyclic lactones. Cats homozygous for the ABCB1 1930_1931del may also be predisposed to such neurological effects, including neurotoxicosis, even at labeled doses. reactions, manifesting as urticaria-like or generalized itching, have been noted in post-approval but occur infrequently. Overall, serious adverse events from post-approval monitoring represent less than 0.5% of reports, with no significant risks observed in breeding, pregnant, or lactating animals. Management of adverse effects focuses on supportive care: if irritation develops at the application site, bathe the animal to remove residual product, and consult a for persistent redness or . Animals should be monitored for 24 to 48 hours post-application for any unusual signs, with most effects resolving spontaneously.

In humans

Selamectin exposure in humans primarily occurs through accidental contact during veterinary application, with common routes including dermal contact, ocular exposure, and rare . Dermal exposure can cause such as redness and pruritus, while prolonged contact may lead to defatting . Ocular exposure results in serious eye , potentially leading to , and requires immediate flushing with water for at least 15 minutes. is uncommon but may occur if a treated pet is licked shortly after application; it is not acutely toxic at typical exposure levels. Reported reactions in humans following accidental exposure include , itching, and swelling, particularly in individuals with , though these are typically mild and resolve without severe outcomes. Reported reactions include mild , with no documented instances of systemic from standard incidental exposures. Repeated occupational exposure, such as among veterinarians, may pose additional risks due to potential accumulation, though data on chronic effects remain limited. FDA-approved labeling for selamectin products warns of potential and eye in humans and advises against direct . Precautions include washing hands thoroughly with soap and water after application, avoiding with treated areas for at least two hours, and wearing protective gloves and eyewear during handling. Selamectin exhibits a low mammalian toxicity profile, supporting its safety when used as directed in veterinary settings.

History

Development

Selamectin is a semisynthetic derivative of the class of compounds, which originated from natural products isolated from the soil bacterium . In the early 1970s, microbiologist at the Kitasato Institute in screened soil samples and identified this bacterium as a producer of novel macrocyclic lactones with potent antiparasitic activity; the extracts were shared with Merck & Co. in 1974, where parasitologist William C. Campbell and his team confirmed their efficacy against helminths in preclinical animal models. This discovery laid the foundation for avermectin-based drugs, earning Ōmura and Campbell the 2015 in Physiology or Medicine for their contributions to antiparasitic therapies. In the 1990s, Animal Health researchers built on this foundation to develop selamectin as a topical endectocide specifically for companion animals, aiming to combine properties against internal parasites like heartworms with ectoparasiticidal effects against fleas and mites. The development process involved extensive preclinical screening of analogs in an feeding assay using the cat (Ctenocephalides felis) to identify compounds with systemic activity against arthropods, revealing a narrow structure-activity relationship where efficacy was primarily associated with structures, particularly those featuring C-5-oxime modifications. Key milestones included optimizing for broad-spectrum activity while prioritizing safety margins suitable for monthly topical administration in dogs and cats, including sensitive breeds like collies. Selamectin emerged as the lead candidate from this screening due to its unique profile: potent kill (effective at concentrations as low as 0.25 μg/mL ) alongside reliable control of nematodes and arthropods, without the toxicity issues seen in earlier . This innovation marked the first derivative formulated to integrate , heartworm prevention, and treatment in a single monthly application, addressing the need for convenient, multifaceted parasite control in pets.

Regulatory approval and introduction

Selamectin received initial regulatory approval from the U.S. (FDA) on May 26, 1999, for topical use in dogs and cats under the brand name (NADA 141-152), targeting fleas, heartworm, ear mites, and certain intestinal parasites. In , the (EMA) granted marketing authorization on November 25, 1999, for the same indications under the name Stronghold. These approvals marked selamectin as the first topical avermectin-class parasiticide for companion animals, enabling monthly applications for broad-spectrum protection. Pfizer Animal Health (now ) launched in the United States and Stronghold in in 2000, rapidly establishing it as a cornerstone in veterinary parasite control. Global expansion followed, with approving selamectin in 2000 for similar uses in dogs and cats. The Australian Pesticides and Veterinary Medicines Authority (APVMA) approved it in 2001, and by 2005, regulatory approvals had been secured in numerous additional countries, including and parts of , solidifying its international presence. Throughout these markets, selamectin has maintained a veterinary prescription-only status to ensure appropriate use and monitoring. In 2019, introduced an expanded formulation, Revolution Plus, combining selamectin with sarolaner; it received FDA approval on November 29, 2018, for enhanced protection against s, ticks, and other parasites in cats. In 2024, the FDA approved supplemental indications for Revolution Plus, including control of the Asian longhorned tick (Haemaphysalis longicornis) on November 13 and prevention of tapeworm infections caused by . Post-market has included ongoing monitoring for potential in target parasites.

Society and culture

Brand names

Selamectin is primarily marketed under the brand name in the , , and by Inc. In and the , it is sold as Stronghold, also by . A combination product, Revolution Plus, which includes selamectin and sarolaner for enhanced flea and tick control in cats, is available in the . Inc., the main manufacturer of these branded products, was spun off from Inc. in June 2013. Following the expiration of the compound patent for selamectin in 2014, generic versions have emerged in limited markets, such as Selehold by KRKA in select regions and Selarid by Norbrook Laboratories Limited in the . All commercial formulations of selamectin are provided as topical solutions in single-dose applicator tubes, calibrated by animal weight, with a typical concentration of 60 mg/mL for and small .

Availability and regulatory status

Selamectin requires a veterinary prescription , where restricts its use to administration by or on the order of a licensed . In the , it is classified as a prescription-only (POM-V), authorized solely by a . Most countries follow similar prescription requirements, though certain formulations are available over-the-counter in regions like without a veterinary prescription. The drug is widely available in , , and the region, supported by established veterinary markets and increasing pet ownership. Availability remains limited in many developing countries, primarily due to high costs and restricted distribution networks. In 2023, the () issued a paper on the environmental of ectoparasiticidal veterinary medicinal products for companion animals, confirming selamectin's safety profile while addressing potential ecological impacts. The review emphasized no immediate risks of withdrawal and recommended labeling updates to mitigate environmental concerns, such as instructions to avoid application near waterways to prevent . In January 2025, the U.S. Food and Drug Administration (FDA) expanded the label for selamectin and sarolaner topical solution (Revolution Plus) for cats to include prevention of tapeworm (Dipylidium caninum) infections by killing fleas, for cats and kittens 8 weeks of age or older weighing at least 2.8 lbs (1.25 kg). In the United States, selamectin typically costs $15-25 per dose, depending on the animal's weight and formulation. Veterinary compounding for off-label uses occurs rarely, subject to strict regulatory oversight.

Similar products

Selamectin, a topical endectocide, shares its class of macrocyclic lactones with , but differs in administration and spectrum of activity. is typically administered orally or via injection for systemic use, offering a narrower spectrum primarily targeting heartworms, intestinal nematodes, and certain ectoparasites like mites, whereas selamectin provides broader coverage against both and ectoparasites through application. Moxidectin serves as another direct comparator within the endectocide group, with a similar broad-spectrum profile against heartworms and other nematodes, but it features a longer elimination —approximately 14 days in topical formulations compared to selamectin's 8-11 days—potentially extending protection intervals for heartworm prevention in some products. Among alternative topical treatments, , as in Frontline, focuses exclusively on ectoparasites such as fleas, ticks, and lice without against heartworms or internal parasites, necessitating with other preventives for comprehensive protection. In contrast, the of and moxidectin in Multi offers topical application with systemic absorption, targeting fleas, heartworms, and intestinal nematodes, but lacks coverage for ticks and requires monthly dosing similar to selamectin. Selamectin's formulation stands out for its single monthly topical dose addressing multiple parasites, reducing the need for multi-product regimens often required with narrower-spectrum options like or pyrethroids, which face emerging in populations. Unlike pyrethroids, selamectin and related macrocyclic lactones show minimal to date. In combination products, Revolution Plus pairs selamectin with sarolaner for enhanced control, providing monthly protection against fleas, , heartworms, and intestinal parasites, while Bravecto Plus combines fluralaner and moxidectin for up to two months of coverage against similar parasites but with a different mechanism for ectoparasites.

References

  1. [1]
    revolution® PLUS - DailyMed
    Nov 29, 2018 · Selamectin paralyzes and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing ...
  2. [2]
    REVOLUTION® (selamectin) - DailyMed
    Revolution kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations ( ...
  3. [3]
    Selamectin | C43H63NO11 | CID 9578507 - PubChem
    Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, ...
  4. [4]
    First study of topical selamectin efficacy for treating cats naturally ...
    Feb 12, 2019 · Topical selamectin is a semi-synthetic macrocyclic lactone that is widely used to prevent heartworm infection. Up until now, there were no ...Missing: avermectin | Show results with:avermectin
  5. [5]
    Selamectin Topical Parasiticide For Dogs and Cats - DailyMed
    Apr 5, 2024 · Selamectin also is indicated for the treatment and control of sarcoptic mange (Sarcoptes scabiei) and for the control of tick infestations due ...
  6. [6]
    [PDF] FOI Summary for the Original Approval of ANADA 200-769 January ...
    Jan 30, 2024 · Dogs: Selamectin kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea ...
  7. [7]
    Efficacy and safety of selamectin against fleas and heartworms in ...
    Selamectin achieved a heartworm prevention rate of 100%, with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300.
  8. [8]
    Prevention of experimentally induced heartworm (Dirofilaria immitis ...
    Selamectin was 100% effective in preventing heartworm development in dogs when administered as a single topical dose of 3 or 6mgkg(-1) at 30 days after ...
  9. [9]
    Evaluation of the effects of selamectin against adult and immature ...
    Reductions in geometric mean flea counts for selamectin compared with saline were >98% between 24 and 36 h after treatment in dogs, and between 12 and 24 h ...
  10. [10]
    Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones - PMC
    The safety of selamectin treatment was specifically analysed in ivermectin-sensitive Collies and it produced no adverse drug reactions, even at supra ...Treatment Of Mdr1 Mutant... · Heartworm Prevention In Dogs... · Mange Treatment In Dogs With...
  11. [11]
    [PDF] FREEDOM OF INFORMATION SUMMARY REVOLUTION™
    Revolution also is indicated for the treatment and control of sarcoptic mange (Sarcoptes scabiei) and for the control of tick (Dermacentor variabilis) ...
  12. [12]
    Efficacy of selamectin against experimentally induced and naturally ...
    Against A. tubaeforme, a single administration of selamectin provided a 99.4% reduction in the geometric mean number of adult worms in cats with natural ...
  13. [13]
    Selamectin - an overview | ScienceDirect Topics
    In the United States, it is approved for the prevention of canine heartworm, flea control, deworming, and the treatment of sarcoptic mange and Otodectes ...Missing: EMA | Show results with:EMA
  14. [14]
    Efficacy of selamectin against biting lice on dogs and cats - PubMed
    Selamectin was 100% effective in killing biting lice on dogs and cats, with significantly lower louse counts compared to placebo.
  15. [15]
    Selamectin Use in Companion Animals | Today's Veterinary Practice
    Aug 4, 2021 · It is important to note that the labeled doses of FDA-approved heartworm prevention products are safe, even in homozygous mutant dogs. Box 1 ...Selamectin Use In Companion... · Efficacy · Revolution PlusMissing: EMA | Show results with:EMA
  16. [16]
    Efficacy of selamectin in the treatment of nasal mite ... - PubMed
    Six of the dogs were treated with selamectin applied to the skin of the back at dosages of 6 to 24 mg/kg for three times at 2-week intervals.
  17. [17]
    A review of the off-label use of selamectin (Stronghold®/Revolution ...
    Selamectin at a dose-rate of 6 mg/kg was effective in one out of three cats on the basis of the elimination of larvae from the faeces after 30 days [16]. To ...
  18. [18]
    Oral selamectin in the treatment of canine generalised demodicosis
    Aug 10, 2025 · A number of macrocyclic lactones used at off-label dosages and regimes have been shown to provide varying levels of effectiveness against ...
  19. [19]
    [PDF] Effectiveness of Using A Single Dose of Selamectin in ... - DergiPark
    Dec 30, 2022 · By microscopic examination of the skin scraping, clinical improvement was observed on the 15th day after a single topical application of 15 mg/ ...
  20. [20]
    Use of selamectin for the treatment of psoroptic and sarcoptic mite ...
    Jan 3, 2007 · Results of the present study suggest that selamectin is effective against naturally infestations of P. cuniculi and S. scabiei in rabbits.
  21. [21]
    Efficacy and safety of selamectin (Stronghold/Revolution) used off ...
    Aug 9, 2025 · Practical experiences and results suggest that selamectin is effective against a variety of ecto- and endoparasites.
  22. [22]
    Antimicrobial therapy for birds (Proceedings) - DVM360
    Apr 1, 2015 · The topical avermectin selamectin has reportedly been used for the treatment of knemidocoptic infections in budgerigars and for the treatment of ...
  23. [23]
    Evaluation of efficacy of selamectin, fipronil, and imidacloprid ...
    Dec 1, 2000 · 8-10 The mechanism of action of aver- mectin compounds in these effects has remained elu- sive; 1 action appears to be an increase in membrane.Missing: review | Show results with:review
  24. [24]
    Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic ...
    Avermectin generally works by preventing the transmission of electrical impulse in the muscle and nerves of invertebrates, by amplifying the glutamate effects ...
  25. [25]
    Glutamate-gated chloride channels and the mode of ... - PubMed
    They exert their anthelmintic effects by binding to glutamate-gated chloride channels expressed on nematode neurones and pharyngeal muscle cells.Missing: selamectin | Show results with:selamectin
  26. [26]
    The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the ...
    The mode of action of avermectins against parasites is well-known: they bind to glutamate-gated chloride channels in nerve and muscle cells, increasing ...
  27. [27]
    Molecular mechanisms of Cys-loop ion channel receptor modulation ...
    May 6, 2012 · Hence, avermectins and milbemycins, which potently activate GluClRs, lethally depress the nervous and muscular system of GluClR-possessing ...
  28. [28]
    Efficacy of selamectin in the prevention of adult heartworm ...
    The efficacy of a novel avermectin, selamectin, was evaluated for the prevention of heartworm disease (adult Dirofilaria immitis infection) in 120 dogs ...
  29. [29]
    Evaluation of the effects of selamectin against adult and ... - PubMed
    Aug 23, 2000 · Selamectin was shown to be highly effective in the treatment and control of flea infestations (C. felis) on dogs and cats. The adulticidal, ...
  30. [30]
    Antiparasitic Drugs for Integumentary Disease in Animals
    In mammals, GABA is found only in the CNS and does not readily cross the blood-brain barrier. At least 10 times the normal dose of ivermectin is needed for ...<|separator|>
  31. [31]
    Safety of Anthelmintics in Animals - Pharmacology
    Mammalian safety appears to depend on P-glycoprotein activity in the blood-brain barrier. P-glycoprotein deficiency in certain animals decreases the ability to ...
  32. [32]
    [PDF] Chanhold; INN-selamectin
    The prolonged persistence and slow elimination of selamectin from plasma is reflected in the terminal elimination half-life values of 8 and 11 days in cats and ...
  33. [33]
    Pharmacokinetics of selamectin following intravenous, oral and ...
    Sep 5, 2002 · Bioavailability was 74% in cats and 4.4% in dogs. Following oral administration to cats, mean Cmax was 11929 ± 5922 ng/mL at Tmax of 7 ± 6 h and ...
  34. [34]
    Stronghold spot-on solution for cats & dogs (GB) - NOAH Compendium
    Selamectin paralyses and/or kills a wide range of invertebrate parasites ... half-life values of 8 and 11 days in cats and dogs respectively. The ...
  35. [35]
    Selamectin - an overview | ScienceDirect Topics
    Topical applications of selamectin provided nearly 100% protection for at least 21 days, and bathing animals with non-insecticidal shampoos did not affect the ...
  36. [36]
    [PDF] Stronghold, INN-selamectin
    The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the ...
  37. [37]
    Selamectin - Mar Vista Animal Medical Center
    Nov 8, 2021 · If selamectin is accidentally consumed orally, it is not toxic but will taste bad, generating salivation and drooling. Vomiting may also result.
  38. [38]
    Adverse Reactions to Spot-on Flea and Tick Products
    Aug 5, 2014 · After bathing off the spot-on product, pets who develop more than mild redness at the application site should be seen by their veterinarians for ...Missing: management | Show results with:management
  39. [39]
    [PDF] SAFETY DATA SHEET - Zoetis
    Sep 24, 2015 · This product is highly flammable, causes serious eye irritation, may cause drowsiness, and is suspected of damaging fertility. It is also toxic ...<|control11|><|separator|>
  40. [40]
    [PDF] revolution-plus-prescribing-information.pdf - Zoetis
    REVOLUTION PLUS kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium ...
  41. [41]
    Human exposure to selamectin from dogs treated with revolution
    Revolution contains the active ingredient selamectin (a semisynthetic avermectin), which controls endoparasites and ectoparasites, including adult fleas, flea ...
  42. [42]
    Selamectin - an overview | ScienceDirect Topics
    A single topical application of selamectin at 12 mg/kg was effective in treating cheyletiellosis in rabbits for up to 5 weeks with no adverse effects.Missing: mange | Show results with:mange
  43. [43]
    History of avermectin and ivermectin, with notes on the ... - PubMed
    The present review provides additional detail, and offers a personal perspective on the history of ivermectin and related avermectins.
  44. [44]
    The 2015 Nobel Prize in Physiology or Medicine - Press release
    Oct 5, 2015 · William C. Campbell and Satoshi Ōmura discovered a new drug, Avermectin, the derivatives of which have radically lowered the incidence of River ...Press Release · English · From Bacteria And Plants To...
  45. [45]
    Avermectins and flea control: structure-activity relationships and the ...
    We discovered commercially exploitable flea activity in a single compound, selamectin 33, which also possessed the necessary antiparasitic spectrum and margin ...Missing: history | Show results with:history
  46. [46]
    Report on Patented Veterinary Drug Product - Revolution
    Dec 6, 2016 · Date of First sale: September 5, 2000. Application of the Excessive ... Revolution (selamectin, Pfizer Canada Inc.) Drug (Brand Name) ...
  47. [47]
    Revolution® for Cats/Rabbits | Zoetis AU
    Revolution is a once-a-month top-spot for dogs, cats and rabbits, with activity against various internal and external parasites.
  48. [48]
    Zoetis Receives FDA Approval for Revolution® Plus
    Nov 29, 2018 · Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Revolution® Plus (selamectin and sarolaner topical ...
  49. [49]
    Resistance of companion animal parasites to antiparasitic drugs
    Resistance may be detected in several ways. Most simply, clearance of the parasite is significantly and repeatedly lower than expected in parasitized animals, ...
  50. [50]
    Revolution® | For Animal Healthcare Professionals - Zoetis
    (selamectin) ... Revolution is a simple-to-apply, quick-drying, small-volume, monthly topical solution that protects against most common feline parasites.How It Works · Important Safety Information · Pet Owner WebsiteMissing: brand worldwide
  51. [51]
    Zoetis Becomes Fully Independent With Acceptance of Pfizer Shares ...
    Jun 24, 2013 · As of today, according to the terms of the exchange offer that commenced on May 22, 2013, Pfizer has accepted shares of Pfizer stock in exchange ...
  52. [52]
    Zoetis Inc. - SEC.gov
    Fostera ® PCV MH was introduced in November 2013 in the United States and approved in the European Union in 2015 and Australia in 2017. ... selamectin ...
  53. [53]
    Selarid® Topical Parasiticide - Norbrook Laboratories
    Selarid® (selamectin) is a topical parasiticide for cats and dogs that can be used to protect against heartworm disease, fleas & more. Learn more today.Missing: brand worldwide
  54. [54]
    Selehold (Generic Revolution) for Cats - CanadaPetCare
    In stock Rating 4.8 (113) Selehold is a spot-on solution for the treatment of multiple cat parasites. Monthly application of Selehold protects cats from flea infestations, biting lice, ...Missing: Selectin | Show results with:Selectin
  55. [55]
    Selamectin - AERU - University of Hertfordshire
    Sep 7, 2025 · Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V). EU Regulatory approval status ... EMA ...
  56. [56]
  57. [57]
    Selamectin API Market Report | Global Forecast From 2025 To 2033
    The global Selamectin API market size was valued at approximately USD 1.2 billion in 2023, and it is projected to reach around USD 2.4 billion by 2032, ...
  58. [58]
    A review of the reflection paper from the EMA - Veterinary Prescriber
    Feb 6, 2023 · A comprehensible review of the EMA's 'reflection paper'. Expert insight surrounding the environmental impact of parasite treatments.
  59. [59]
    Selamectin (Revolution) Prices - U.S. & International
    4.6 434 The lowest price on PharmacyChecker.com for Selamectin (Revolution) 15mg/0.25ml is $9.42 per applicator for 6 applicators at PharmacyChecker-accredited online ...Missing: dose | Show results with:dose
  60. [60]
    Ectoparasiticides Used in Small Animals - Pharmacology
    Five macrocyclic lactones are used in formulations marketed for control of external parasites in dogs and cats: selamectin, ivermectin, and eprinomectin.
  61. [61]
    Brain penetration of ivermectin and selamectin in mdr1a,b P ...
    Jan 13, 2009 · In contrast to ivermectin, selamectin is safer in the treatment of MDR1 mutant dogs, suggesting that selamectin is transported differently by P-glycoprotein ...
  62. [62]
    A review of moxidectin vs. other macrocyclic lactones for prevention ...
    Jun 24, 2024 · Moxidectin has beneficial pharmacokinetic characteristics, such as a longer half-life and greater tissue distribution compared to ivermectin.
  63. [63]
    Moxidectin for Dogs - Today's Veterinary Practice
    Jun 15, 2022 · Pharmacokinetic studies in dogs have demonstrated a terminal half-life of about 342 hours.9. Finally, when administered orally at much lower ...
  64. [64]
    Comparison of the activity of selamectin, imidacloprid and fipronil for ...
    Comparison of the activity of selamectin, imidacloprid and fipronil for the treatment of dogs infested experimentally with Ctenocephalides canis and ...
  65. [65]
    Efficacy of imidacloprid + moxidectin and selamectin topical ...
    Sep 13, 2011 · In study #1 imidacloprid + moxidectin and the selamectin formulation provided 99.8% and 99.0% efficacy at 24 hours post-treatment. On day 28, ...Missing: ivermectin | Show results with:ivermectin
  66. [66]
    Comparative efficacy of topical treatments with Revolution® Plus ...
    Treatment with fluralaner (Bravecto® for Cats) provided high and consistent efficacy of ≥99.3% up to Day 70. On Day 84, efficacy was 90.1%; however, cats from ...
  67. [67]
    Comparative efficacy of topical treatments with Revolution® Plus ...
    Jun 3, 2019 · Revolution Plus had ≥99.1% efficacy for 30 days, while Bravecto had ≥99.3% up to 70 days, and both provided >90% control over 12 weeks.Missing: moxidectin | Show results with:moxidectin